Therapeutic strategy for ALK/ROS driven NSCLC

Jan Van Meerbeeck (Belgium)

Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Number: 10

Disease area: Thoracic oncology

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Jan Van Meerbeeck (Belgium). Therapeutic strategy for ALK/ROS driven NSCLC. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.